AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30420184 — intervention group
Group type: EXPERIMENTAL
Intervention: LDS + EZE + ALP (triple combination)
Number of subjects: 100
Study 30420184 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 100
Study 29303450 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous preservation of autologous bone flap
Number of subjects: 193
Study 29303450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranioplasty with autologous bone
Number of subjects: 193
Study 29303450 — intervention group
Group type: COMPARATOR
Intervention: Custom synthetic implant
Number of subjects: 193
Study 27476886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 transfusion ratio of plasma and platelets to red blood cells
Number of subjects: 0
Study 27476886 — intervention group
Group type: COMPARATOR
Intervention: 1:1:2 transfusion ratio of plasma and platelets to red blood cells
Number of subjects: 0
Study 27476886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 transfusion ratio
Number of subjects: 0
Study 27476886 — intervention group
Group type: COMPARATOR
Intervention: 1:1:2 transfusion ratio
Number of subjects: 0
Study 24888540 — intervention group
Group type: EXPERIMENTAL
Intervention: Icterometer group (IG)
Number of subjects: 352
Study 24888540 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 352
Study 22581821 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation over the intact right Broca's homologue
Number of subjects: 18
Study 22581821 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 18
Study 20881505 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise periodized resistance exercise program with 100 swings a day, 3 days/week for 12 weeks (Group 1)
Number of subjects: 49
Study 20881505 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise periodized resistance exercise program with additional rotational and full-body medicine ball exercises, 3 days/week for 12 weeks (Group 2)
Number of subjects: 49
Study 20881505 — intervention group
Group type: COMPARATOR
Intervention: Stepwise periodized resistance exercise program (Group 1)
Number of subjects: 49
Study 20881505 — intervention group
Group type: COMPARATOR
Intervention: Stepwise periodized resistance exercise program with additional exercises (Group 2)
Number of subjects: 49
Study 19016270 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologic Intervention plus assessment
Number of subjects: 227
Study 19016270 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 227
Study 15748122 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation plus suction
Number of subjects: 15
Study 15748122 — intervention group
Group type: COMPARATOR
Intervention: Suction alone
Number of subjects: 15
Study 12091067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg/daily orally in three doses plus morphine escalation
Number of subjects: 156
Study 12091067 — intervention group
Group type: COMPARATOR
Intervention: Morphine only
Number of subjects: 156
Study 12091067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac-morphine group
Number of subjects: 156
Study 12091067 — intervention group
Group type: COMPARATOR
Intervention: Morphine group
Number of subjects: 156
Study 10334415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice daily for 4 weeks)
Number of subjects: 10
Study 8610602 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 43
Study 8288175 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day methadone detoxification coupon
Number of subjects: 4390
Study 8288175 — intervention group
Group type: COMPARATOR
Intervention: 21-day methadone detoxification coupon
Number of subjects: 4390
Study 3016134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (1 microgram/kg per min)
Number of subjects: 0
Study 3016134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30354493 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA-specific definitions of high-risk plaque features
Number of subjects: 472
Study 30354493 — intervention group
Group type: COMPARATOR
Intervention: IVUS definitions
Number of subjects: 472
Study 27653887 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2mA for four 20-minute sessions)
Number of subjects: 21
Study 27653887 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study 25587645 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d lisdexamfetamine
Number of subjects: 259
Study 25587645 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg/d lisdexamfetamine
Number of subjects: 259
Study 25587645 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d lisdexamfetamine
Number of subjects: 259
Study 25587645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 24101042 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionation intensity‐modulated radiation therapy (CIMRT) - 76 Gy in 38 fractions at 2.0 Gy per fraction
Number of subjects: 303
Study 24101042 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated IMRT (HIMRT) - 70.2 Gy in 26 fractions at 2.7 Gy per fraction
Number of subjects: 303
Study 21744190 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of stickers and criteria for switch to oral antimicrobial therapy to the drug chart in the study group post-intervention
Number of subjects: 85
Study 21744190 — intervention group
Group type: COMPARATOR
Intervention: Conventional practice of clinical pharmacists reviewing drug charts and contacting prescribers to discuss a switch to an oral antimicrobial in the control group
Number of subjects: 85
Study 21744190 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group post-intervention
Number of subjects: 85
Study 21744190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 19565559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular infliximab
Number of subjects: 23
Study 19565559 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular methylprednisolone
Number of subjects: 23
Study 16738023 — intervention group
Group type: EXPERIMENTAL
Intervention: External explanation for violation of equality
Number of subjects: 0
Study 16738023 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of trust in others
Number of subjects: 0
Study 16738023 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced high trust with external explanation being a lie
Number of subjects: 0
Study 16738023 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution information
Number of subjects: 0
Study 15305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing from coronary sinus and/or posterior right atrium at different cycle lengths (900 to 400 ms; duration: 30 to 60 s)
Number of subjects: 15
Study 15305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol administration
Number of subjects: 15
Study 15305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine administration
Number of subjects: 15
Study 15305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid sinus massage (CSM)
Number of subjects: 15
Study 11738309 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.1 mg/kg)
Number of subjects: 54
Study 11738309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (1.0 mg/kg)
Number of subjects: 54
Study 9789898 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS members (Group III)
Number of subjects: 448
Study 9789898 — intervention group
Group type: COMPARATOR
Intervention: Patients with symptoms from Group I
Number of subjects: 448
Study 9789898 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS members
Number of subjects: 448
Study 9789898 — intervention group
Group type: COMPARATOR
Intervention: Non-member group
Number of subjects: 448
Study 7905095 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment (HET)
Number of subjects: 63
Study 7905095 — intervention group
Group type: COMPARATOR
Intervention: H pylori positive
Number of subjects: 63
Study 7905095 — intervention group
Group type: COMPARATOR
Intervention: H pylori negative
Number of subjects: 63
Study 2721334 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 2.0 mg/kg
Number of subjects: 5
Study 2721334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29605395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dextrose gel (0.5 mL/kg) rubbed into the buccal mucosa
Number of subjects: 236
Study 29605395 — intervention group
Group type: COMPARATOR
Intervention: Control group (feedings alone)
Number of subjects: 236
Study 27743922 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated non-peritoneal metastatic colorectal cancer
Number of subjects: 10553
Study 27743922 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more non-peritoneal sites of metastasis
Number of subjects: 10553
Study 27743922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal metastatic colorectal cancer plus one other site of metastasis
Number of subjects: 10553
Study 27743922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal metastases and two or more additional sites of metastasis
Number of subjects: 10553
Study 24201177 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive Ethics Intervention
Number of subjects: 384
Study 24201177 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 384
Study 23076338 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (26-week multidisciplinary treatment programme)
Number of subjects: 112
Study 20858829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (15 HU and 600 mg I/kg)
Number of subjects: 195
Study 20858829 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (12 HU and 521 mg I/kg)
Number of subjects: 195
Study 20858829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols B and C (15 HU and 521 mg I/kg; 15 HU and 600 mg I/kg)
Number of subjects: 195
Study 20858829 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols A and C (12 HU and 521 mg I/kg; 15 HU and 600 mg I/kg)
Number of subjects: 195
Study 18479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day
Number of subjects: 0
Study 18479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/day
Number of subjects: 0
Study 18479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg/day
Number of subjects: 0
Study 18479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg/day
Number of subjects: 0
Study 18479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 0
Study 18479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 80 mg/day
Number of subjects: 0
Study 18479175 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole vs Pantoprazole (milligram-per-milligram comparison)
Number of subjects: 0
Study 15845680 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate/Desflurane (ETO/DES)
Number of subjects: 49
Study 15845680 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of Propofol
Number of subjects: 49
Study 15845680 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled (MAN) Propofol Infusion
Number of subjects: 49
Study 12887343 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (Emdogain, BIORA AB, Malmo, Sweden) applied subgingivally
Number of subjects: 22
Study 12887343 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 22
Study 10472324 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy with Mitomycin C
Number of subjects: 178
Study 10472324 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy alone
Number of subjects: 178
Study 2239143 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CR CBZ)
Number of subjects: 48
Study 2239143 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbamazepine (CBZ)
Number of subjects: 48
Study 402795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) administered orally, 20 mg three times a day for 3 weeks (double-blind study)
Number of subjects: 9
Study 402795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) administered orally, 20 mg four times a day for 2 weeks (open controlled study)
Number of subjects: 9
Study 402795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) administered orally
Number of subjects: 9
Study 31568199 — intervention group
Group type: EXPERIMENTAL
Intervention: Striving app
Number of subjects: 290
Study 31568199 — intervention group
Group type: EXPERIMENTAL
Intervention: Boning Up e-book
Number of subjects: 290
Study 31568199 — intervention group
Group type: COMPARATOR
Intervention: Wait List
Number of subjects: 290
Study 31026734 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma (enacted and internalized)
Number of subjects: 444
Study 31026734 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of public settings used for drug consumption (shooting gallery, crack house, abandoned building, public bathroom, outside)
Number of subjects: 444
Study 28234790 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 0.2 μg/kg/min
Number of subjects: 20
Study 28234790 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine 5 μg/kg/min
Number of subjects: 20
Study 26021668 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term (8-week) intensive online Bone Power program
Number of subjects: 866
Study 26021668 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer term (12-month) Bone Power Plus program including a 10-month online booster intervention (biweekly eHealth newsletters)
Number of subjects: 866
Study 23705624 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based sampling by mailed test-kit
Number of subjects: 216
Study 23705624 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based testing without appointment
Number of subjects: 216
Study 23705624 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall chlamydia positivity rate at retest
Number of subjects: 216
Study 23705624 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Dutch participants
Number of subjects: 216
Study 23705624 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting symptoms
Number of subjects: 216
Study 21482966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust inhalation
Number of subjects: 19
Study 21482966 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle trap
Number of subjects: 19
Study 21482966 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 19
Study 20139575 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Herbal toothpaste
Number of subjects: 30
Study 20139575 — intervention group
Group type: COMPARATOR
Intervention: Colgate toothpaste (control)
Number of subjects: 30
Study 17327524 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 284
Study 17327524 — intervention group
Group type: COMPARATOR
Intervention: Present-centered therapy
Number of subjects: 284
Study 15295221 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of sunflower seed oil 3 times daily
Number of subjects: 103
Study 15295221 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 103
Study 11602220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Harass
Number of subjects: 42
Study 11602220 — intervention group
Group type: COMPARATOR
Intervention: Friend-Harass
Number of subjects: 42
Study 9640214 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy (BCT)
Number of subjects: 278
Study 9640214 — intervention group
Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 278
Study 8023354 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-microns arterial line filter
Number of subjects: 100
Study 8023354 — intervention group
Group type: COMPARATOR
Intervention: No arterial line filter
Number of subjects: 100
Study 3181323 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccine developed in chick embryo cells
Number of subjects: 0
Study 3181323 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccines developed in human diploid cells (HDC)
Number of subjects: 0
Study 3181323 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccine developed in baby calf kidney cells
Number of subjects: 0
Study 436923 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 4 mg/kg
Number of subjects: 8
Study 436923 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 1 mg/kg
Number of subjects: 8
Study 436923 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.2 mg/kg
Number of subjects: 8
Study 436923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31648187 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of testosterone
Number of subjects: 49
Study 31648187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31090457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve A1 supplementation for 12 weeks
Number of subjects: 121
Study 31090457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 28263901 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aquatic resistance training (48 sessions over 4 months)
Number of subjects: 87
Study 28263901 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal physical activity)
Number of subjects: 87
Study 28263901 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time physical activity (LTPA)
Number of subjects: 87
Study 25466317 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation only
Number of subjects: 31
Study 25466317 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation plus daily interruption (DI)
Number of subjects: 31
Study 25466317 — intervention group
Group type: COMPARATOR
Intervention: Daily interruption (DI)
Number of subjects: 31
Study 23820000 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AF)
Number of subjects: 0
Study 23820000 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed casein-based formula (HF)
Number of subjects: 0
Study 22594137 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice daily)
Number of subjects: 8
Study 22594137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose pill twice daily)
Number of subjects: 8
Study 20190130 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic risk and exposed to depression
Number of subjects: 1159
Study 20190130 — intervention group
Group type: COMPARATOR
Intervention: Low genetic risk and without phenotypic expression of depression
Number of subjects: 1159
Study 20190130 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability without phenotypic expression of depression
Number of subjects: 1159
Study 18198639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) treatment for 14 days
Number of subjects: 80
Study 18198639 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 15990619 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for ocular hypertension with NNT of 20 for average patients, NNT of 6 for those with IOP > or =26 mm Hg.
Number of subjects: 20
Study 15990619 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting higher risk patients for treatment.
Number of subjects: 20
Study 15990619 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative initial glaucoma treatment study (CIGTS) justifying primary surgery.
Number of subjects: 20
Study 15990619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular hypertension public health intervention.
Number of subjects: 20
Study 15990619 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG public health intervention.
Number of subjects: 20
Study 12027853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate infusion
Number of subjects: 0
Study 12027853 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 0
Study 10073846 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 5000
Study 10073846 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 5000
Study 8903978 — intervention group
Group type: EXPERIMENTAL
Intervention: Topicaina spray (benzocaine butyl aminobenzoate, amethocaine, butacaine)
Number of subjects: 256
Study 8903978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 1978605 — intervention group
Group type: COMPARATOR
Intervention: saline (group 1)
Number of subjects: 100
Study 1978605 — intervention group
Group type: EXPERIMENTAL
Intervention: tubocurarine 0.05 mg/kg (group 2)
Number of subjects: 100
Study 1978605 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.006 mg/kg (group 3)
Number of subjects: 100
Study 1978605 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.025 mg/kg (group 4)
Number of subjects: 100
Study 1978605 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg/kg (group 5)
Number of subjects: 100
Study 298360 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 24
Study 298360 — intervention group
Group type: COMPARATOR
Intervention: mesoridazine
Number of subjects: 24
Study 31804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine wafer implantation followed by chemoradiotherapy with temozolomide
Number of subjects: 250
Study 31804699 — intervention group
Group type: COMPARATOR
Intervention: Standard maximal resection followed by chemoradiotherapy with temozolomide
Number of subjects: 250
Study 28280109 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (2 h of exercise in the heat with no fluid intake)
Number of subjects: 10
Study 28280109 — intervention group
Group type: COMPARATOR
Intervention: Control (2 h of exercise with ad libitum fluid intake)
Number of subjects: 10
Study 28280109 — intervention group
Group type: COMPARATOR
Intervention: Rest (time-matched rest period)
Number of subjects: 10
Study 26297883 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaF+9% HMP
Number of subjects: 12